Clinical trial · Interventional
Personalized Radiation Therapy for GBM
Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
NCT03477513CI-TRIAL-00117253completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single Arm
- description
- Dose-escalated radiation therapy
- interventionNames
- Radiation: Radation Therapy
Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen * Age 18 or older * Ability to give signed informed consent * Karnofsky Performance Status (KPS) at least 70 Exclusion Criteria: * Placement of Gliadel wafers * Participation in another investigational trial * Active treatment of another malignancy
References
Publications (1)
- DERIVEDAkbari H, Mohan S, Liu F, Jiang C, Fathi Kazerooni A, Berger M, Rathore S, Bilello M, Sako C, Garcia J, Brem S, Bakas S, Mamourian E, Pepin A, James P, Dorsey J, Singh A, Parker D, Verma R, Cao Q, Bagley SJ, Desai A, O'Rourke DM, Shinohara RT, Nasrallah MP, Teo BK, Kurtz G, Shukla G, Alonso-Basanta M, Lustig RA, Davatzikos C. Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study. Nat Commun. 2026 May 13;17(1):6413. doi: 10.1038/s41467-026-72545-y. PMID 42129213